Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Up 107.4% in January

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 1,210,000 shares, a growth of 107.4% from the December 31st total of 583,500 shares. Currently, 9.2% of the shares of the company are sold short. Based on an average daily trading volume, of 203,100 shares, the days-to-cover ratio is currently 6.0 days.

Sensus Healthcare Trading Up 19.8 %

SRTS stock traded up $1.36 during midday trading on Friday, hitting $8.23. The stock had a trading volume of 713,769 shares, compared to its average volume of 187,031. Sensus Healthcare has a 52 week low of $2.91 and a 52 week high of $9.33. The stock has a 50-day simple moving average of $7.50 and a 200 day simple moving average of $6.84. The firm has a market capitalization of $134.89 million, a price-to-earnings ratio of 14.44 and a beta of 1.21.

Analysts Set New Price Targets

A number of brokerages have recently commented on SRTS. HC Wainwright upped their price target on Sensus Healthcare from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Monday, November 18th. Maxim Group increased their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a report on Friday, November 15th. Finally, Lake Street Capital began coverage on shares of Sensus Healthcare in a report on Friday. They set a "buy" rating and a $18.00 price objective on the stock.

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in SRTS. Truvestments Capital LLC acquired a new position in Sensus Healthcare in the third quarter worth about $32,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $95,000. Cubist Systematic Strategies LLC bought a new position in shares of Sensus Healthcare during the 2nd quarter worth approximately $156,000. Ritholtz Wealth Management boosted its stake in Sensus Healthcare by 65.3% in the 4th quarter. Ritholtz Wealth Management now owns 51,261 shares of the company's stock valued at $355,000 after buying an additional 20,256 shares in the last quarter. Finally, Marshall Wace LLP grew its position in Sensus Healthcare by 152.4% in the second quarter. Marshall Wace LLP now owns 77,387 shares of the company's stock valued at $412,000 after acquiring an additional 46,732 shares during the period. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.